Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
January 3, 2025 News by Marisa Wexler, MS. Health issues seen in MS children in 5 years before diagnosis: Study. In the five years leading up to a multiple sclerosis (MS) diagnosis, children and ...
Top 10 MS news stories of 2024
Dec 31, 2024 · The most-read stories published by Multiple Sclerosis News Today in 2024 focused on living with MS and news on disease risk factors. Top 10 MS news stories of 2024
1-year fenebrutinib inhibits nearly all MS signs in relapsing MS trial
Sep 6, 2024 · The Phase 2 FENopta trial (NCT05119569) evaluated fenebrutinib’s safety and efficacy in 109 adults, ages 18-55, with relapsing forms of MS, including relapsing-remitting MS and active secondary ...
Top 10 MS stories of 2023 - Multiple Sclerosis News Today
News; Top 10 MS stories of 2023 Top 10 MS stories of 2023. Of most interest to readers was news on potential treatments, triggers. by Marisa Wexler, MS | January 2, 2024.
MRI analysis of MS ReBUILD data shows remyelination with...
Jun 16, 2023 · Top 10 MS news stories of 2024; Recommended reading. October 8, 2024 News by Esteban Domínguez Cerezo, MS. Nerve stimulator for myelin repair to enter RRMS clinical trial.
The MS News Today Podcast - Multiple Sclerosis News Today
After 24 years with the National MS Society, most recently as Chief Advocacy, Services and Science Officer, Dr. Tim Coetzee is the new President and CEO of the Society.
MS news notes: Stem cell therapy, early Aubagio use, DMTs
May 1, 2023 · Stem cell therapy receives a good report card. The MS News Today article “AAN 2023: Low rates of disease activity after stem cell transplant” reports on a follow-up study of 22 autologous ...
MS news notes: Vaccines, migraines, eye-tracking technology
Sep 18, 2023 · The MS News Today story “No greater risk of hospitalization found after vaccines in MS in study” reports on a nationwide study in France involving over 100,000 people, that “found no ...
Stable MS patients free of disease activity after DMT stops: Study
Dec 18, 2024 · Nearly all participants (89.9%) had relapsing-remitting MS, while the remaining had secondary progressive MS.Most were women (67.4%), with a median age of 54, and the median time since the last ...
MS news notes: Stem cell therapy, genetic variant, diet
Jul 3, 2023 · The MS News Today article “Stem cell therapy highly effective in active RRMS: Real-world study” reports that nearly 80% of participants with highly active relapsing-remitting multiple ...